Device-Measured Physical Activity and Cognitive Processing Speed Impairment in a Large Sample of Persons with Multiple Sclerosis

2020 ◽  
Vol 26 (8) ◽  
pp. 798-805
Author(s):  
Brian M. Sandroff ◽  
Robert W. Motl
Keyword(s):  
Physical Activity ◽  
Multiple Sclerosis ◽  
Cognitive Processing ◽  
Processing Speed ◽  
Cross Sectional ◽  
Actual Problem ◽  
Large Sample ◽  
Beneficial Effects ◽  
Disability Status ◽  
Cognitive Processing Speed

AbstractObjective:There is accumulating evidence regarding the beneficial effects of physical activity (PA) on cognitive processing speed in persons with multiple sclerosis (MS). However, one overarching limitation of this research is that researchers have not recruited samples who have the actual problem of being studied (i.e., cognitive processing speed impairment). This study examined associations between device-measured PA and cognitive processing speed in a large sample of persons with MS overall and between those with and without cognitive processing speed impairment.Method:Three hundred eighty-five persons with MS underwent the oral Symbol Digit Modalities Test (SDMT) and wore an accelerometer for 7 days for PA measurement. We divided the overall sample into subsamples with (n = 140) and without (n = 245) cognitive processing speed impairment based on age, sex, and education-adjusted SDMT Z-scores.Results:After controlling for age and disability status, higher levels of device-measured PA were significantly associated with faster cognitive processing speed overall, and the association was significantly stronger among persons with MS who presented with cognitive processing speed impairment.Conclusions:This examination provides initial cross-sectional support for informing the development of PA interventions as a possible approach for managing MS-related cognitive processing speed impairment. This highlights the importance of developing purposefully designed trials involving PA interventions for targeting cognitive processing speed as a primary end point among persons with MS with impaired cognitive processing speed.

Physical Activity and Cognitive Function in Multiple Sclerosis

2011 ◽  
Vol 33 (5) ◽  
pp. 734-741 ◽  
Author(s):  
Robert W. Motl ◽  
Eduard Gappmaier ◽  
Kathryn Nelson ◽  
Ralph H.B. Benedict
Keyword(s):  
Physical Activity ◽  
Multiple Sclerosis ◽  
Cognitive Impairment ◽  
Learning And Memory ◽  
Cognitive Processing ◽  
Processing Speed ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Neuropsychological Assessments ◽  
Cognitive Processing Speed

Cognitive impairment is prevalent, disabling, and poorly managed in persons with multiple sclerosis (MS). This cross-sectional study examined the associations among physical activity, cognitive processing speed, and learning and memory in 33 persons with MS who underwent neuropsychological assessments and wore a physical activity monitor for 7 days. Cognitive impairment was greatest in cognitive processing speed. Physical activity was significantly correlated with cognitive processing speed (pr = .35), but not learning and memory (pr = .20), after controlling for sex, age, and education. Researchers should examine exercise training and physical activity effects on cognitive performance, particularly processing speed, in MS.

Physical activity is associated with cognitive processing speed in persons with multiple sclerosis

2014 ◽  
Vol 3 (1) ◽  
pp. 123-128 ◽  
Author(s):  
Brian M. Sandroff ◽  
Deirdre Dlugonski ◽  
Lara A. Pilutti ◽  
John H. Pula ◽  
Ralph H.B. Benedict ◽  
...  
Keyword(s):  
Physical Activity ◽  
Multiple Sclerosis ◽  
Cognitive Processing ◽  
Processing Speed ◽  
Cognitive Processing Speed

scholarly journals Improvement of Attention, Executive Functions, and Processing Speed in Elderly Women as a Result of Involvement in the Nordic Walking Training Program and Vitamin D Supplementation

Nutrients ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 1311 ◽  
Author(s):  
Mariusz Lipowski ◽  
Tamara Walczak-Kozłowska ◽  
Małgorzata Lipowska ◽  
Jakub Kortas ◽  
Jędrzej Antosiewicz ◽  
...  
Keyword(s):  
Physical Activity ◽  
Vitamin D ◽  
Depressive Symptoms ◽  
Cognitive Functioning ◽  
Cognitive Processing ◽  
Processing Speed ◽  
Elderly Women ◽  
Vitamin D Supplementation ◽  
Nordic Walking ◽  
Cognitive Processing Speed

Research indicates that life satisfaction declines with age, and cognitive abilities are gradually reduced—mainly attentional functioning and cognitive processing speed. Therefore, scientists seek to find protective factors and test possible intervention programs; moderately intensive physical activity stands out as particularly promising. In this context, we evaluated the influence of Nordic Walking training supported by vitamin D supplementation (as this nutrient is especially deficient in older people in Poland) on the cognitive and psychological functioning of elderly women. A total of 52 healthy elderly women took part in a Nordic Walking training program complemented by vitamin D supplementation. Cognitive functioning was assessed with the Trail Making Test and the D2 Test of Attention. Quality of life and severity of depressive symptoms were measured with the Short Form Health Survey and the Beck Depression Inventory 2. Significant improvements in all aspects of cognitive functioning was observed (p = 0.01–0.47). The study also showed a decrease in depressive symptoms (p = 0.026). Physical activity and adequate levels of vitamin D can be the key factors in maintaining self-reliance in old age. Involvement in Nordic Walking training, supported by vitamin D supplementation, can strengthen the cognitive functioning of older people—reflected in higher attentional capabilities, better executive functions, and improved cognitive processing speed.

Myelin Damage in Normal Appearing White Matter Contributes to Impaired Cognitive Processing Speed in Multiple Sclerosis

2020 ◽  
Vol 30 (2) ◽  
pp. 205-211
Author(s):  
Shawna Abel ◽  
Irene Vavasour ◽  
Lisa Eunyoung Lee ◽  
Poljanka Johnson ◽  
Nathalie Ackermans ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
White Matter ◽  
Cognitive Processing ◽  
Processing Speed ◽  
Normal Appearing White Matter ◽  
Cognitive Processing Speed ◽  
Myelin Damage

Cognitive Processing Speed Is Related to Fall Frequency in Older Adults With Multiple Sclerosis

2013 ◽  
Vol 94 (8) ◽  
pp. 1567-1572 ◽  
Author(s):  
Jacob J. Sosnoff ◽  
Swathi Balantrapu ◽  
Lara A. Pilutti ◽  
Brian M. Sandroff ◽  
Steven Morrison ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Older Adults ◽  
Cognitive Processing ◽  
Processing Speed ◽  
Cognitive Processing Speed

scholarly journals Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study

2017 ◽  
Vol 24 (6) ◽  
pp. 795-804 ◽  
Author(s):  
Ralph HB Benedict ◽  
Stanley Cohan ◽  
Sharon G Lynch ◽  
Katherine Riester ◽  
Ping Wang ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Processing ◽  
Processing Speed ◽  
Cognitive Outcomes ◽  
High Yield ◽  
Meaningful Improvement ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Cognitive Processing Speed

Background: Cognitive impairment is common in multiple sclerosis (MS), with cognitive processing speed being the most frequently affected domain. Objective: Examine the effects of daclizumab beta versus intramuscular (IM) interferon (IFN) beta-1a on cognitive processing speed as assessed by Symbol Digit Modalities Test (SDMT). Methods: In DECIDE, patients with relapsing–remitting multiple sclerosis (RRMS) (age: 18–55 years; Expanded Disability Status Scale (EDSS) score 0–5.0) were randomized to daclizumab beta ( n = 919) or IM IFN beta-1a ( n = 922) for 96–144 weeks. SDMT was administered at baseline and at 24-week intervals. Results: At week 96, significantly greater mean improvement from baseline in SDMT was observed with daclizumab beta versus IM IFN beta-1a ( p = 0.0274). Significantly more patients treated with daclizumab beta showed clinically meaningful improvement in SDMT (increase from baseline of ⩾3 points ( p = 0.0153) or ⩾4 points ( p = 0.0366)), and significantly fewer patients showed clinically meaningful worsening (decrease from baseline of ⩾3 points ( p = 0.0103)). Odds representing risk of worsening versus stability or improvement on SDMT were significantly smaller for daclizumab beta ( p = 0.0088 (3-point threshold); p = 0.0267 (4-point threshold)). In patients completing 144 weeks of treatment, the effects of daclizumab beta were generally sustained. Conclusion: These results provide evidence for a benefit of daclizumab beta versus IM IFN beta-1a on cognitive processing speed in RRMS. Trial registration: ClinicalTrials.gov identifier NCT01064401 (Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis (DECIDE)): https://clinicaltrials.gov/ct2/show/NCT01064401 .

Sign in / Sign up

Export Citation Format

Share Document